Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden
Observational analysis reveals varied responses to immune checkpoint inhibitors in tumors, highlighting key predictors.
Key Points
Higher progression-free survival is linked to immune checkpoint inhibitor sensitivity and no liver metastasis, suggesting specific patient profiles may benefit more.
A total of 117 patients were evaluated, with 34% overall response rate to immune checkpoint inhibitors, emphasizing the variability in treatment outcomes.
Analysis utilized Kaplan-Meier and univariable tests to discern the impact of clinical and genetic variables on therapy responses, underpinning targeted assessments.
Findings may enable better patient stratification for immune checkpoint inhibitor therapy based on tumor characteristics and mutational status, improving outcomes.